A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants with PNH
Study Identifier:
ALXN2040-PNH-303
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruitment Complete
Study Details
Medical Condition
- Paroxysmal Nocturnal Hemoglobinuria
Study Drug
- Drug: Danicopan
Date
Oct 2022 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: n/a - n/a
Requirements Information
Sex
Female & Male
Age
n/a - n/a
Study Details
Medical Condition
- Paroxysmal Nocturnal Hemoglobinuria
Study Drug
- Drug: Danicopan
Date
Oct 2022 - Jul 2026
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: n/a - n/a years
Requirements Information
Protocol Summary
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
Trial Locations
Location
Status
Location
Research Site
Seoul, Unmapped, 03722
Status
Active, not recruiting
Location
Research Site
Kyoto-shi, Japan, 605-0981
Status
Completed
Location
Research Site
Gdańsk, Poland, 80-952
Status
Active, not recruiting
Location
Research Site
Jerusalem, Unmapped, 91120
Status
Active, not recruiting
Location
Research Site
Dallas, TX, United States, 75390-9047
Status
Completed
Location
Research Site
Cleveland, OH, United States, 44195
Status
Completed